Explore more price target data and ratings for Azenta, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Azenta, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a…
Q3 revenue and profitability exceeded expectations, driven by strong growth in recurring revenue businesses and Multiomics in Europe and China, while North America showed modest improvement. FY 2026 guidance was raised, but the outlook remains cautious due to uneven demand and ongoing headwinds in…
Revenue grew 12% year-over-year to $161M, driven by Sample Management Solutions and Multiomics. Adjusted EBITDA margin was 11.4%, with FY26 guidance for flat to 1% organic revenue growth and $59–$62M adjusted EBITDA. B Medical Systems sale closed, and $50M in shares were repurchased.Original docume…
Azenta reported third-quarter fiscal 2026 results for the period ended June 30, 2026, with revenue from continuing operations of $161.2 million and non-GAAP diluted EPS of $0.16. Adjusted EBITDA from continuing operations was $18.5 million and adjusted EBITDA margin was 11.4%. The company noted org…
AZTA (Azenta, Inc.) is set to announce its Q3'26 results on August 04, after the market closes. The earnings are expected to be disclosed at 4:00 PM ET (8:00 PM UTC).For Q3'26, revenue estimate is 149.24 million USD with EPS (earnings per share) anticipated at 0.11 USD. Learn more details at AZTA F…
Life sciences company Azenta NASDAQ:AZTA will be reporting results this Tuesday after the bell. Here’s what investors should know.Azenta missed analysts’ revenue expectations last quarter, reporting revenues of $144.8 million, flat year on year. It was a disappointing quarter for the company, with…
Azenta finalized documentation supporting the completed sale of B Medical, agreeing to a $35 million vendor loan to buyer Thelema at 6% interest with a three-month maturity. The loan is secured by a first-priority pledge over 100% of B Medical’s equity and may be subordinated or released upon refin…
